Pertuzumab its development and potential for use in the treatment of breast cancer
By
TABLE OF CONTENTS
ABSTRACTII
LITERATURE REVIEW1
Summary1
Aims1
Findings1
Conclusion2
Key Words2
General Introduction and Background2
Stages of Breast Cancer3
Symptoms of Breast Cancer3
Diagnosis of Breast Cancer4
Current Treatment4
Usage of Pertuzumab in Breast Cancer5
ErbB2 (h-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) and Breast Cancer6
Mechanisms of action of Pertuzumab7
Exploring acquired resistance to pertuzumab11
Clinical Relevance13
Discussion and Conclusion14
Limitations and Strengths of the Study15
REFERENCES16
ABSTRACT
The prevalence of breast cancer is one of the most debated issues in the British society. This paper presents a literature review on the topic of breast cancer and the usage of pertuzumab for its treatment. Breast cancer originates in the mammary gland, the functional structure of the adult breast. Most breast cancers originate from the epithelial cells of the terminal ductal-lobular unit (TDLU), comprised of the lobule and adjacent ducts.
LITERATURE REVIEW
Summary
Management of breast cancer is transdisciplinary involving clinical examination, imaging diagnostics, pathology, surgery, radiation oncology, and medical oncology. Most treatment regimes begin with some form of surgery for local disease control, followed by local and/or systemic adjuvant therapies (Franklin, et al. 2004, 319). Different types of surgery include: breast conserving surgery (BCS) and modified radical mastectomy (MRM) (Keating, 2012, 353). Complications arising from breast cancer among women have been the most debated issues in recent times. This literature review presents an in-depth knowledge about the clinical effectiveness of pertuzumab in the treatment of breast cancer.
Aims
The aims of this particular literature review are to:
Discuss the prevalence of breast cancer among women
Explore the effectiveness of pertuzumab in the treatment of breast cancer
Explain the clinical relevance of pertuzumab
Findings
Women from all treatment groups were sacrificed at treatment day 144 due to poor general health, which could be associated with the long-term administration of CTX, systemic response to the multiple antibody-based therapies used, or a consequence of bearing tumours for greater than 180 days.
Conclusion
In the pertuzumab-resistance study, pertuzumab was more effective at blocking and delaying tumour growth than any of the other therapeutic strategies, but all therapies showed some delay in tumour growth compared to the group maintained on pertuzumab alone. Pertuzumab tends to slow down the rate of tumour growth, without a complete delay in tumour growth (Franklin, et al. 2004, 35). The anti-tumour effect of these three therapies was similar for approximately 14 days, at which time the tumour growth rate in women treated with pertuzumab or cetuximab began to increase.(Mullen, et al. 2007, 11337).
Key Words
Breast, Cancer, Pertuzumab, Clinical, Treatment, ErbB2, Women General Introduction and Background
Breast cancer originates in the mammary gland, the functional structure of the adult breast. Most breast cancers originate from the epithelial cells of the terminal ductal-lobular unit (TDLU), comprised of the lobule and adjacent ducts. There currently exist two models for the development of breast cancer (Slamon, 2001).
The incidence of breast cancer in developed countries such as the United States, United Kingdom, Australia, and developing countries of Latin America and South East Asia has revealed astonishing geographical variations. Since the 1940s the incidence of breast cancer among women has ...